Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 8 studies | 26% ± 7% | |
astrocyte | 6 studies | 30% ± 10% | |
epithelial cell | 4 studies | 29% ± 4% | |
GABAergic neuron | 4 studies | 35% ± 11% | |
glutamatergic neuron | 4 studies | 39% ± 12% | |
oligodendrocyte precursor cell | 4 studies | 26% ± 7% | |
endothelial cell | 3 studies | 21% ± 4% | |
interneuron | 3 studies | 34% ± 16% | |
neuron | 3 studies | 26% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 3609.25 | 2642 / 2642 | 100% | 22.50 | 705 / 705 |
prostate | 100% | 1559.88 | 245 / 245 | 100% | 12.81 | 502 / 502 |
skin | 100% | 1255.48 | 1807 / 1809 | 100% | 12.09 | 472 / 472 |
ovary | 100% | 1540.61 | 180 / 180 | 100% | 10.52 | 429 / 430 |
bladder | 100% | 1470.48 | 21 / 21 | 100% | 9.75 | 502 / 504 |
intestine | 100% | 1327.33 | 966 / 966 | 99% | 9.42 | 524 / 527 |
uterus | 100% | 1226.31 | 170 / 170 | 99% | 9.53 | 456 / 459 |
thymus | 99% | 1186.38 | 649 / 653 | 100% | 11.77 | 604 / 605 |
breast | 100% | 1146.55 | 459 / 459 | 99% | 12.18 | 1109 / 1118 |
kidney | 100% | 1241.48 | 89 / 89 | 99% | 11.25 | 893 / 901 |
pancreas | 99% | 863.46 | 326 / 328 | 99% | 7.22 | 177 / 178 |
stomach | 99% | 988.06 | 356 / 359 | 100% | 8.65 | 285 / 286 |
adrenal gland | 100% | 1914.72 | 258 / 258 | 99% | 8.97 | 227 / 230 |
esophagus | 100% | 1282.40 | 1444 / 1445 | 98% | 7.07 | 180 / 183 |
liver | 98% | 757.37 | 221 / 226 | 99% | 5.89 | 403 / 406 |
lung | 97% | 865.51 | 560 / 578 | 100% | 9.34 | 1153 / 1155 |
eye | 0% | 0 | 0 / 0 | 100% | 12.26 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 11.01 | 29 / 29 |
spleen | 100% | 1090.54 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 6.89 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.20 | 1 / 1 |
blood vessel | 100% | 1191.09 | 1331 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 1093.13 | 1200 / 1204 | 0% | 0 | 0 / 0 |
heart | 95% | 1016.36 | 822 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 687.46 | 762 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 41% | 537.45 | 383 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006367 | Biological process | transcription initiation at RNA polymerase II promoter |
GO_0000502 | Cellular component | proteasome complex |
GO_0005669 | Cellular component | transcription factor TFIID complex |
GO_0016251 | Molecular function | RNA polymerase II general transcription initiation factor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PAAF1 |
Protein name | Proteasomal ATPase associated factor 1 Proteasomal ATPase-associated factor 1 (Protein G-16) (WD repeat-containing protein 71) |
Synonyms | WDR71 |
Description | FUNCTION: Inhibits proteasome 26S assembly and proteolytic activity by impairing the association of the 19S regulatory complex with the 20S core. In case of HIV-1 infection, recruited by viral Tat to the HIV-1 promoter, where it promotes the recruitment of 19S regulatory complex through dissociation of the proteasome 26S. This presumably promotes provirus transcription efficiency. Protects SUPT6H from proteasomal degradation. . |
Accessions | ENST00000546039.5 F5H103 Q9BRP4 F5H3I1 ENST00000536582.5 ENST00000543814.5 H0YGB1 F5H5D4 ENST00000542293.5 ENST00000541951.5 [Q9BRP4-3] ENST00000310571.8 [Q9BRP4-1] ENST00000504441.6 F5H0F7 ENST00000535604.5 [Q9BRP4-3] ENST00000536003.5 [Q9BRP4-2] F5H0C4 ENST00000544552.5 [Q9BRP4-2] ENST00000376384.9 [Q9BRP4-2] F5H3E9 ENST00000544909.5 ENST00000540659.1 |